Two Dutch companies – DDL, a state-of-the-art laboratory specializing in molecular diagnostic testing and assay development and ENPICOM, an innovative immunomics data analysis company – Today announced that they have started a collaboration to jointly deliver immune repertoire sequencing and analysis service to organizations studying immune system related diseases or developing drugs influencing this system.
Immune repertoire sequencing is a powerful way to analyze hundreds of thousands to millions of T or B cell receptors swiftly and in a cost-effective way. This new technology is rapidly gaining interest from researchers and physicians who want to unravel the adaptive immune responses in areas like basic and translational immunology, immuno-oncology, autoimmune disorders, inflammatory and infectious diseases, vaccine research and transplantation. From target discovery to patient stratification in clinical trials with immunotherapies, repertoire sequencing is becoming an important addition to accelerate the different drug development processes and make it more cost-effective.
“DDL is very pleased to start this partnership with ENPICOM in this new and challenging field of immunomics”, says Jan Lindeman, DDL’s Chief Executive Officer. “It further expands DDL’s portfolio of tailor-made molecular diagnostic services for our (bio)pharmaceutical customers. ENPICOM’s expertise and know-how are highly complementary to DDL’s expertise and we are confident that this partnership will offer a unique opportunity to accelerate immunotherapy discovery and development.”
Jos Lunenberg, ENPICOM’s Chief Executive Officer comments: “Last month we launched our IGX platform to manage, store, analyze, visualize and interpret immune repertoire sequencing data from T and B cell receptors. Now we are also able to support organizations lacking the specific expertise or capabilities to perform repertoire sequencing with our smart new analysis and visualization methods. In DDL we have found a highly respected business partner with an excellent track record as molecular diagnostic testing laboratory for the biopharmaceutical industry. I’m very pleased to be able to go public with this partnership today.” He continues: “There are a few other kits and services for this specific form of targeted sequencing available in the market, but none or very limited data analysis is included. Clonality analysis is just a first step to bridge the existing gap between producing raw sequencing data and obtaining important insights from the data. So, in essence, we start where others stop.”